Australia markets open in 4 hours 51 minutes

Rubius Therapeutics Inc (5RT.SG)

Stuttgart - Stuttgart Delayed price. Currency in EUR
Add to watchlist
0.1990+0.0020 (+1.02%)
As of 04:24PM CET. Market open.
Full screen
Previous close0.1970
Open0.2000
Bid0.2020 x 0
Ask0.2140 x 0
Day's range0.1990 - 0.2000
52-week range0.1970 - 11.8000
Volume0
Avg. volume169
Market capN/A
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings date23 Feb 2023 - 27 Feb 2023
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    Rubius Therapeutics Announces Process to Explore Strategic Alternatives and Leadership Changes

    Dannielle Appelhans to Become President and Chief Executive Officer Pablo J. Cagnoni, M.D., Appointed Chair of the Board of Directors CAMBRIDGE, Mass., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a biopharmaceutical company that is developing an entirely new class of cellular medicines called Red Cell Therapeutics™ for the treatment of cancer and autoimmune diseases, today announced that it has initiated a process to explore a range of strategic alternatives to ma

  • GlobeNewswire

    Rubius Therapeutics to Present at Guggenheim Nantucket Therapeutics Conference

    CAMBRIDGE, Mass., Sept. 19, 2022 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a biopharmaceutical company that is developing an entirely new class of cellular medicines called Red Cell Therapeutics™ for the treatment of cancer and autoimmune diseases, today announced that Pablo J. Cagnoni, M.D., president and chief executive officer, will participate in a fireside chat at the Guggenheim Nantucket Therapeutics Conference on Thursday, September 29, 2022, at 11:15am EDT. A live aud

  • GlobeNewswire

    Rubius Therapeutics Announces Strategic Update

    Company to Focus on Advancing Next Generation Red Blood Cell-Based Cell Conjugation Platform Initiating Cost-Saving Measures Through Corporate Restructuring; Cash Runway Extended to End of 2023 Discontinuing Ongoing Phase 1 Clinical Trials of RTX-240 and RTX-224 in Advanced Solid Tumors Investor Teleconference and Webcast Scheduled Today at 7:30 a.m. EDT CAMBRIDGE, Mass., Sept. 13, 2022 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a biopharmaceutical company that is developing a